Status:
COMPLETED
Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer
Lead Sponsor:
AstraZeneca
Conditions:
Locally Advanced Prostate Cancer
Eligibility:
MALE
18-80 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine if the addition of ZD1839 Iressa™ to standard treatment with Casodex® (bicalutamide) for locally advanced prostate cancer can detect a difference in the rate ...
Eligibility Criteria
Inclusion
- 18 to 80 years of age. Men with histologically confirmed locally advanced prostatic adenocarcinoma
Exclusion
- No prior treatment for prostate cancer, including surgery, radiotherapy, cryotherapy or thermotherapy. No abnormal laboratory values. No co-existing malignancies and any other significant clinical disorder or laboratory finding.
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
End Date :
August 1 2006
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT00319787
Start Date
December 1 2003
End Date
August 1 2006
Last Update
January 25 2011
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Moelv, Norway
2
Research Site
Oslo, Norway
3
Research Site
Trondheim, Norway